Rognli EB, et al. - Researchers examined the prospective association of cannabis use with prescription of antipsychotics, mood stabilizers, antidepressants and anxiolytics. From the longitudinal Young in Norway Study, data of 2,602 individuals on cannabis exposure and relevant confounders were obtained. Analysis revealed an increased risk of prescription of antipsychotics (OR = 5.56, 95 % CI 1.64 – 18.87), mood-stabilizers (OR = 5.36, 95 % CI 1.99 – 14.44) and antidepressants (OR = 2.10, 95 % CI 1.36 – 3.25) in correlation with past-year cannabis use, after accounting for socio-demographic variables, conduct problems, additional drug use, mental distress, and prescriptions the year before cannabis use was measured.